PROTAC HSP90 degrader BP3 |
Catalog No.GC64825 |
Le dégradeur PROTAC HSP90 BP3 est une dégradation puissante et sélective de HSP90 de manière dépendante du CRBN. Le dégradeur PROTAC HSP90 BP3 a un certain effet de dégradation sur la protéine HSP90 dans les cellules MCF-7 (DC50 = 0,99 μM). Le dégradeur PROTAC HSP90 BP3 inhibe la croissance des cellules cancéreuses du sein.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2669072-88-0
Sample solution is provided at 25 µL, 10mM.
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain certain degradation effect on HSP90 protein in MCF-7 cells (DC50=0.99 µM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell[1].
PROTAC HSP90 degrader BP3 (compound 16b) (72 h) inhibits the growth of breast cancer cells (IC50=0.63 µM in MCF-7 cells, IC50=3.53 µM in MDA-MB-231 cells, IC50=0.61 µM in 4T1 cells, IC50=2.95 µM in MDA-MB-468 cells)[1].PROTAC HSP90 degrader BP3 (2 µM; 6 h) shows degradation activity in the MCF-7 cells (DC50=0.99 µM)[1].
PROTAC HSP90 degrader BP3 (40 mg/kg; i.p., daily for 12 days) inhibits tumor growth and the tumor inhibition rate is 76.41%[1].
[1]. Liu Q, et al. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. Eur J Med Chem. 2022, 228:114013.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *